Hong Kong stock movement: TRANSTHERA-B stock price soared 12.85%, domestic stock conversion to H shares plan ignites market enthusiasm

Hong Kong Stock Movement

TRANSTHERA-B rose 12.85%. According to recent important news:

1. On October 22, TRANSTHERA-B announced that it is considering and has approved the submission of an application to the China Securities Regulatory Commission to convert 44,971,128 domestic shares into H shares, accounting for approximately 11.33% of the company's total issued shares. This move triggered a positive market reaction, leading to a significant increase in stock price. Data source: Huigang Communications

2. On October 20, TRANSTHERA-B announced its plan to convert domestic shares into H shares and list on the main board of the Stock Exchange. This news enhanced market expectations for the company's future growth, driving the stock price up. Data source: Jinshi Data

3. On October 20, TRANSTHERA-B released an announcement on the Hong Kong Stock Exchange regarding the domestic share conversion plan, further boosting market expectations for its cash flow and growth potential, resulting in a rise in stock price. Data source: 36Kr Innovation Drug Sector is active, with significant capital inflow, caution is needed for volatility risks.

Stocks with High Trading Volume in the Industry

Innovent Biologics fell 0.17%. According to recent important news:

1. On October 22, Innovent Biologics reached a global strategic cooperation with Takeda Pharmaceutical, involving the development of next-generation IO and ADC therapies. This cooperation includes a $1.2 billion upfront payment and a total transaction amount of up to $11.4 billion, driving stock price fluctuations. Source: Innovent Biologics Announcement

2. On October 22, after the announcement of the cooperation with Takeda Pharmaceutical, Innovent Biologics' stock price briefly rose nearly 10%, but then fell back due to profit-taking and a decline in market risk appetite. Source: Zhitong Finance

3. On October 22, the cooperation between Innovent Biologics and Takeda Pharmaceutical was seen by the market as recognition of the company's innovative technology platform, enhancing investor confidence. Source: Caixin Network Hong Kong stock liquidity increased, and attention to innovative drugs rose.

Kangfang Biologics fell 2.34%. According to recent important news:

1. On October 21, Kangfang Biologics announced that its partner Summit plans to submit a Biologics License Application for Ivosidenib in combination with chemotherapy to the U.S. FDA, driving stock price fluctuations. The drug has been approved in China and included in medical insurance, showing potential for global market expansion;

2. On October 20, Kangfang Biologics presented the results of the HARMONi-6 study at the ESMO conference, showing that Ivosidenib in combination with chemotherapy significantly improved PFS, with data published in The Lancet, enhancing market confidence;

3. On October 21, CMB International released a research report maintaining a target price of HKD 183 for Kangfang Biologics, expressing long-term optimism and recommending a buy, reflecting the market's optimistic expectations for the company's future development. The valuation center for innovative drugs in the biologics industry has been adjusted downward.

Rongchang Biologics fell 3.22%. According to recent important news:

1. On October 22, Huatai Securities released a research report indicating that Rongchang Biologics' core products have recently had intensive clinical results readout, accelerating the company's overseas expansion. The report believes that the company's domestic sales are steadily growing, and it is expected that annual revenue growth may exceed 30%, which supports the stock price;

2. On October 21, Rongchang Biologics presented the Phase III study results of Vedolizumab at the ESMO conference, receiving positive market feedback, which led to significant fluctuations in its stock price during trading;

3. On October 22, CMB International raised the target price for Rongchang Biologics to HKD 109, maintaining a "Buy" rating, reflecting the market's optimistic expectations for the company's clinical data and sales prospects. The innovative drug sector showed a divergent trend, with significant capital flow.

Stocks ranked among the top in industry market capitalization

BeiGene fell by 2.68%. According to recent important news:

1. On October 20, the Deputy Director of BeiGene's Hong Kong and Macau operations revealed that BTK inhibitors and IL-6 inhibitors have been included in the Hong Kong government's drug list, and the core product PD-1 inhibitor "Breztri" is under review, with expectations for more products to be approved for the Hong Kong market. This news boosted market expectations for the company's future growth, but did not significantly impact the stock price in the short term.

2. On October 20, a Vice President of BeiGene pointed out that the production capacity advantages of the Guangzhou production base provide flexibility in cost control for "Breztri," and the drug has passed triple certification from the U.S. FDA, EU EMA, and domestic NMPA, with plans to enter more international markets in the future. Although the long-term outlook is positive, the market response has been tepid in the short term.

3. On October 21, market analysis indicated that domestic companies are continuously increasing R&D investment, enhancing the competitiveness of innovative drugs in the global market. Positive changes in policies also provide important support for the commercialization and internationalization of innovative drugs. Despite these factors being favorable for BeiGene's long-term development, they have not significantly boosted the stock price in the short term. Industry R&D investment is increasing, and policies support the internationalization of innovative drugs